SERVIER
Servier and Taiho Pharmaceutical Co., Ltd. today announced clinical data from the pivotal Phase III trial (TAGS) for LONSURF® (trifluridine and tipiracil, TAS-102) which showed significant improvement in overall survival (OS) for the treatment of patients with refractory metastatic gastric cancer (HR=0.69 [95% IC 0.56-0.85], p=0.0003). The median overall survival in patients treated with trifluridine/tipiracil and best supportive care (BSC) was 5.7 months as compared to 3.6 months when treated with placebo and BSC, and they had a 31% risk reduction of death. At 12-months, OS rates were 21.2% in the trifluridine/tipiracil group and 13.0% in the placebo group. In addition, the risk for disease progression measured by PFS, a key secondary endpoint, was reduced by 43% (HR: 0.57).
The overall safety profile was consistent with the known safety profile of trifluridine/tipiracil in metastatic colorectal cancer (CRC), with mainly hematological adverse events reported.
“The results presented today from TAGS demonstrate the potential of trifluridine/tipiracil in this group of patients with late-stage metastatic gastric cancer”, said Professor Josep Tabernero. Head of the Medical Oncology Department, Vall d’Hebron University Hospital, Barcelona and Director of the Vall d’Hebron Institute of Oncology (VHIO). “Patients at this stage of the disease have very few remaining therapeutic options and it is important that efficacious and manageable treatments are available to expand patient’s survival.”
Ali Zeaiter, Head of Servier Oncology Clinical Development Department added, “We are pleased that trifluridine/tipiracil has shown significant benefit for patients with metastatic gastric cancer who are in need of effective treatments when there are few options remaining. We are committed to improving patients’ outcomes and to providing access to new therapeutic options. We will continue to collaborate with regulatory bodies to progress our mission to make trifluridine/tipiracil accessible to patients and medical professionals.”
Trifluridine/tipiracil is currently indicated in Europe for the treatment of adult patients with metastatic CRC who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents.1
About TAGS
TAGS (TA S-102 G astric S tudy) is a Taiho-sponsored pivotal Phase III multinational, randomized, double-blind study evaluating trifluridine and tipiracil, plus best supportive care (BSC) versus placebo plus BSC in patients with metastatic gastric cancer refractory to standard treatments. The primary endpoint in TAGS is overall survival (OS), and secondary endpoint measures include progression-free survival (PFS), safety and tolerability, as well as quality of life.
TAGS enrolled 507 adult patients with metastatic gastric cancer who had previously received at least two prior regimens for advanced disease. The trial was conducted in Europe, Russia, Turkey, Japan, and North America.
For more information on TAGS, please visit www.ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02500043 ). The ClinicalTrials.gov Identifier is NCT02500043.
About Metastatic Gastric Cancer
Gastric cancer, also known as stomach cancer, is a disease in which malignant cells form in the lining of the stomach. It is the fifth most common cancer worldwide and the third most common cause of cancer-related death (after lung and liver cancer), with an estimated 723,000 deaths annually.2 Approximately 50 percent of patients with gastric cancer have advanced disease at the time of diagnosis.3
Standard chemotherapy regimens for advanced gastric cancer include fluoropyrimidines, platinum derivatives, and taxanes, or irinotecan. The addition of trastuzumab to chemotherapy is standard of care for patients with HER2-neu-positive advanced gastric cancer. However, after failure of first- and second-line therapies, standard third line treatments are limited.
About LONSURF ® (trifluridine and tipiracil, TAS-102)
LONSURF® is an oral anticancer drug, comprising a combination of trifluridine (FTD) and tipiracil (TPI), whose dual mechanism of action is designed to maintain clinical activity. LONSURF® is registered in Japan, USA, European Union and in many other countries. In the European Union, LONSURF® is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapies, anti-VEGF agents, and anti-EGFR agents.i
LONSURF® is recommended by the National Institute for Health and Care Excellence (NICE),4 NCCN5,6 and ESMO Guidelines7 for the treatment of adult patients with metastatic colorectal cancer.
In June 2015, Servier and Taiho Pharmaceutical entered into an exclusive license agreement for the co-development and commercialization of LONSUF® .
About Servier
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 148 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,600 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Becoming a key player in oncology is part of Servier’s long-term strategy. Currently, there are nine molecular entities in clinical development in this area, targeting gastric and lung cancers and other solid tumors, as well as different types of leukemia and lymphomas. This portfolio of innovative cancer treatments is being developed with partners worldwide, and covers different cancer hallmarks and modalities, including cytotoxics, proapoptotics, immune, cellular and targeted therapies, to deliver life-changing medicines to patients.
More information: www.servier.com
Find us on Social Media:
About Taiho Pharmaceutical Co., Ltd. (Japan)
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (https://www.otsuka.com/en/ ), is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people's quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people's efforts to lead fulfilling and rewarding lives.
For more information about Taiho Pharmaceutical, please visit: https://www.taiho.co.jp/en/ .
1
European Medicines Agency. Lonsurf. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003897/human_med_001975.jsp&mid=WC0b01ac058001d124
Last accessed May 2018.
2
Ferlay J, Soerjomataram I,
Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D,
Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide:
IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency
for Research on Cancer; 2013. Available from: http://globocan.iarc.fr
3
National Comprehensive Cancer Network (NCCN). Clinical Practice
Guidelines in Oncology. Gastric cancer. V.1.2018.
4
NICE
TA405. Available at: www.nice.org.uk/guidance/TA405
Last accessed May 2018.
5
National Comprehensive Cancer
Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
6
National Comprehensive Cancer Network (NCCN). NCCN Guidelines for
Patients: Rectal Cancer, Version 1.2017.
7
ESMO
consensus guidelines for the management of patients with metastatic
colorectal cancer: Van Cutsem E et al. Ann Oncol. 2016;27:1386-422.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005476/en/
Contact:
Servier
Sonia MARQUES
media@servier.com
Tél.
+33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
or
Karine
BOUSSEAU
media@servier.com
Tél.
+33 (0)1 55 72 60 37
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Group: Q4 and Full Year Financial Results 2024/2522.5.2025 06:21:00 CEST | Press release
Lenovo delivers strong full-year performance – innovation and operational excellence further strengthen competitiveness Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today announced Q4 and full year results for the fiscal year 2024/25, reporting significant increases in overall group revenue and profit. For the full year, revenue grew 21% year-on-year to US$69.1 billion, marking the Group’s second-highest annual revenue in its history. Net income was up 36% year-on-year to US$1.4 billion on a non-Hong Kong Financial Reporting Standards (non-HKFRS[1]) basis. The Group’s diversified growth engines continue to accelerate, with non-PC revenue mix up nearly five points year-on-year to 47%. All business groups were healthy and strong and met their strategic intent and financial goals, and all sales geographies gained double-digit revenue growth year-on-year, reflecting the strength of the Group’s diversified businesses and resilient global footpr
Mastercard and OCTO Join Forces to Promote Responsible Driving Through Loyalty Programs21.5.2025 18:10:00 CEST | Press release
Thanks to Mastercard’s SessionM platform, OCTO will offer valuable incentives to more responsible drivers while increasing customer engagement and loyalty to insurance companies. Mastercard and OCTO, a global leader in advanced telematics solutions and data analytics services for the insurance and automotive sectors, today announce a collaboration aimed at redefining the interaction between insurance companies and customers by encouraging safer driving behaviors through an innovative loyalty program. The partnership involves the integration of Mastercard’s SessionM – a platform designed to support businesses in managing customer loyalty and engagement – with OCTO’s patented scoring models, which assess driving behavior using either physical devices (black boxes) or digital solutions (apps). This agreement has a dual objective: for drivers, it provides tangible benefits such as discounts on auto, home, and travel insurance, as well as other rewards, in exchange for safe and responsible
Boomi Recognized as a Leader for the 11th Time in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service21.5.2025 17:30:00 CEST | Press release
Boomi Believes Its Leadership in AI, API Management, and Data Management Advancements Will Drive Strong Customer and Partner Momentum Boomi™, the leader in AI-driven automation, today announced it has been recognized as a Leader in the 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS), for the 11th consecutive time – the longest in the report’s history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521105444/en/ In our opinion, Boomi’s continued industry recognition reflects its unwavering commitment to innovation, customer success, and ecosystem growth. Over the past year, Boomi has accelerated its investments in AI agent management, API management, and data management to help enterprises connect everything with one platform and drive intelligent automation at scale. Key advancements include: Launch of Boomi Agentstudio for AI Agent Management: Boomi recently introduced the only full agent life
Textron Aviation Announces Fleet Order for up to 12 Cessna Citation Business Jets From Aerolineas Ejecutivas21.5.2025 17:00:00 CEST | Press release
Textron Aviation today announced it has entered into a purchase agreement with Aerolíneas Ejecutivas (ALE), Mexico’s leading business aviation company, for up to 12 Cessna Citation business jets. ALE will operate the aircraft — a mix of Cessna Citation Latitude, Citation CJ3 Gen2 and Citation CJ3 Gen3 business jets — in its fractional ownership division, MexJet. ALE expects to take delivery of four aircraft, including two Citation Latitudes and two Citation CJ3 Gen2 aircraft, in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521263551/en/ Textron Aviation announces fleet order for up to 12 Cessna Citation business jets from Aerolineas Ejecutivas. (Photo Credit: Textron Aviation) The Cessna Citation business jets are designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “Cessna Citation business jets are ideal for fractional customers seeking class-leading comfort and performance,” sa
ElastiFlow and Rohde & Schwarz Collaborate To Deliver Unmatched Network Traffic Insights21.5.2025 16:00:00 CEST | Press release
ElastiFlow, a pioneer in the observability space, today announced a strategic partnership with Rohde & Schwarz, one of the world’s leading manufacturers of test and measurement, secure communications, monitoring and network testing, and broadcasting equipment. This collaboration aims to improve network visibility and data enrichment capabilities for enterprises worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521910528/en/ Network flow data, in the form of IPFIX records, is essential for understanding network traffic, detecting anomalies, and ensuring optimized performance and robust security. The new alliance leverages ElastiFlow to enrich IPFIX records from Rohde & Schwarz solutions, transforming raw data into actionable insights. This enables rapid, real-time detection of network events, security threats, and application performance issues. The collaboration allows for deep packet inspection (DPI) technology t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom